Most competitor profiles I've seen are useless.
They're a SWOT table, a revenue figure, a pipeline snapshot, and a paragraph that says something like "Company X is a major player in the cardiovascular space." That's not a profile. That's a Wikipedia entry. It describes the present. It doesn't predict behavior, assess threat, or tell you what to do about it.
A real competitor profile is a living analytical document. It connects a competitor's strategy, capabilities, clinical data, and commercial positioning into a picture that answers one question: what is this competitor likely to do, and what does that mean for us?
The difference matters. The descriptive profile tells you that a competitor has a Phase III compound. The strategic profile tells you when that compound is likely to reach market, how it threatens your positioning, what scenarios could play out at launch, and what contingency plans you need in place now. One sits on a shelf. The other drives action.
Building profiles that actually move strategy requires discipline in three areas: knowing which competitors deserve a deep dive, structuring the profile around the right analytical framework, and keeping it current. This article walks through all three.
Before you build a profile, you need to figure out who deserves one. This sounds obvious, but it's one of the most underestimated challenges in competitive intelligence. Most teams default to profiling whoever they already know about. That's comfortable, but it creates blind spots.
Research on competitor identification identifies four distinct lenses, and each one reveals something different.
The industry lens defines competitors as all firms in the same product or geographic market. It's the default starting point — who's in our space? — and it works for establishing the broad competitive landscape. But it misses non-obvious threats from adjacent spaces. In pharma, a competitor with a different mechanism of action in a neighboring indication might be more dangerous than the obvious player in your direct space.
The strategic groups lens recognizes that not all firms compete equally. Competitors are those that occupy similar strategic positions — comparable resources, capabilities, market approaches. A small biotech with a single asset and limited commercial reach competes differently than a large pharma company with a full field force and established KOL relationships. Understanding where competitors cluster helps predict intensity of rivalry.
The manager-oriented lens acknowledges that competitors are partly constructed through perception. When managers' mental models are outdated or narrow, competitive blind spots emerge. I've seen this happen repeatedly — a brand team so focused on the direct competitor in their mechanism of action class that they completely missed a disruptive entrant from a different therapeutic approach. What you think the competitive set looks like is not always what it actually looks like.
The customer lens identifies competitors by analyzing who customers see as alternatives. In pharma, this means understanding which products physicians consider interchangeable, which therapies patients switch between, and which treatments payers group together in formulary decisions. This perspective frequently reveals threats that supply-side analysis misses entirely.
The practical takeaway: relying on any single perspective creates gaps. The competitors you profile in depth should come from multiple lenses, not just the obvious industry view.
There's another layer. Not all competitors pose the same kind of threat.
Direct competitors have similar products in the same indication, targeting the same patient population. These are the ones everyone watches.
Indirect competitors offer alternative solutions — a different mechanism of action, a different treatment approach, a non-pharmaceutical intervention. They're easy to underestimate and hard to track, because the competitive signal is weaker.
Potential competitors don't compete with you today but could enter your space. A company with a strong platform technology in a neighboring indication. A large pharma player with an unannounced early-stage program. These are the ones that catch teams off guard.
There's also a concept called competitive asymmetry that matters here: the fact that "Company A sees Company B as a competitor" does not mean "Company B sees Company A as a competitor." Smaller companies watch larger ones closely. The reverse is often not true. If you're a biotech with a single Phase II asset, you're acutely aware of the big pharma company with a Phase III program in your space. They may not even know you exist yet. Understanding this asymmetry — and when it shifts — is important intelligence.
Be selective. A deep competitor profile takes significant analytical time to build and maintain. Most teams should have 2–5 deep profiles covering their most direct competitive threats, with broader landscape monitoring for the rest.
The question isn't "how many competitors exist?" — it's "which ones will most affect our strategic decisions in the next 12–24 months?" Those are the ones that get the deep dive.
The framework I use for competitor deep dives has nine elements. Each one serves a specific purpose, and the structure deliberately moves from context to assessment to action. It's not just an information-gathering exercise. It's an analytical framework that ends with what you're going to do.
Start with the competitor's broader strategy. What is their corporate vision? What are their stated priorities? Where does this product fit in their portfolio?
A competitor with a single late-stage asset has a very different strategic calculus than one where the product in question is the fourth priority in a diversified portfolio. Understanding this context shapes everything that follows — their likely level of investment, their tolerance for risk, their willingness to compete aggressively on price or positioning.
Questions to answer: What is the competitor's overall SWOT? What is their current financial situation, and how does it affect their ability to invest? What position does this product hold within their broader portfolio? What partnerships and external relationships strengthen their position? What is their organizational structure and leadership?
These are not theoretical questions. The answers tell you how hard this competitor is going to fight.
Timeline analysis is one of the highest-value elements of a competitor profile. When is this product likely to reach market?
But a single date is misleading. What you actually need is a range — with uncertainty explicitly acknowledged. The expected launch date should be derived from benchmarking against analog programs (similar mechanism of action, similar indication, similar regulatory pathway), adjusted for what you know about the competitor's accrual rates, their regulatory strategy, and any signals from their public filings.
In pharma pipeline analysis, timeline estimation is part science, part judgment. Clinical trial registries give you enrollment status and expected completion dates. Earnings calls sometimes reveal management's own timeline expectations. But trials get delayed, regulatory agencies issue complete response letters, manufacturing problems emerge. Your timeline analysis has to model that uncertainty, not hide it.
Not all competitors are equally dangerous. A threat level assessment — high, medium, or low — forces a prioritization decision.
Threat level is a function of three things: the strength of the competitor's clinical data (or expected data), their commercial capability and organizational readiness, and their timeline relative to yours. A competitor with strong efficacy data, an established field force, and a launch date six months ahead of yours is a high threat. A competitor with mixed Phase II data, no commercial infrastructure, and an uncertain regulatory path is a low threat — today. Threat levels change. They need to be reassessed at every major event.
The value of making the assessment explicit is that it forces the organization to align on what "threatening" actually means. I've seen brand teams where the medical director rates a competitor as high threat based on the clinical data while the commercial lead rates the same competitor as low threat because they don't have sales force coverage. Both are right — they're just looking at different dimensions. The structured assessment makes those different views visible and reconcilable.
The TPP comparison is where you put your product and the competitor's product side by side on the dimensions that matter. Mechanism of action, efficacy endpoints, safety profile, dosing regimen, route of administration, expected label, pricing position.
This isn't a table you build once. It evolves as clinical data matures. Early in development, much of the competitor TPP is based on inference — what does their trial design suggest about their expected efficacy claims? What do their inclusion/exclusion criteria reveal about their target patient population? As data becomes public, the TPP sharpens.
The TPP comparison directly feeds your positioning strategy. If the competitor's product has a convenience advantage (once-weekly vs. daily dosing), you need to know that early enough to shape your messaging around clinical superiority. If they have a safety signal you don't, that's a positioning opportunity. The TPP is where clinical intelligence becomes commercial intelligence.
This is the core of product-level intelligence. You need to understand the competitor's registration trial in detail: trial design, patient population, primary and secondary endpoints, efficacy results (if available), and safety profile.
What are the PK, PD, and PE studies competitors are conducting, and what do the designs reveal about their strategy? What is the size and structure of their trials? What do their inclusion/exclusion criteria reveal about their positioning? What primary and secondary endpoints are they using, and how do they differ from yours? What is their enrollment status and milestone progress?
In pharma CI, ClinicalTrials.gov is the baseline source, but it's just the starting point. Conference presentations, journal publications, investor day presentations, and FDA advisory committee documents all add depth. The analytical step is what matters — not just documenting what the trial looks like, but interpreting what the design choices mean for competitive positioning.
I'll give you an example. If a competitor includes a novel safety endpoint in their trial that isn't standard for the indication, that's a signal. They may be planning to make a differentiated safety claim. Understanding that early enough to refine your own protocol — or at least prepare your messaging — is the kind of intelligence that creates competitive advantage.
SWOT — strengths, weaknesses, opportunities, threats — is one of the most familiar frameworks in business. Its familiarity is both its strength and its weakness. Everyone knows how to fill in the four quadrants. Very few do it well.
A competitor SWOT that matters is specific, evidence-based, and connected to action. "Strong brand" in the strengths quadrant tells you nothing. "Established relationships with 80% of top-50 prescribers in our indication, based on 5 years of MSL engagement" tells you what you're up against and what it would take to compete.
The SWOT should integrate everything else in the profile — clinical data feeds strengths and weaknesses, timeline and commercial capability feed threats, market dynamics feed opportunities. It's a synthesis, not a standalone exercise.
This is where the profile moves from description to prediction. What are the likely scenarios for this competitor's launch?
Build at least three: base case (most likely outcome based on current data and timeline), downside case (what happens if things go worse than expected for the competitor), and worst case (what happens if everything goes right for them and wrong for you).
Scenarios should be specific enough to trigger different strategic responses. "Competitor launches successfully" is not a scenario. "Competitor launches 6 months ahead of us with a favorable ODAC vote, rapid formulary uptake due to competitive pricing, and 40% physician awareness within 3 months" — that's a scenario you can plan against.
The scenario work connects directly to the competitive simulations and war games that many organizations use to pressure test strategy. In a war game, participants step into the competitor's shoes and simulate their likely moves. The pre-read for that exercise draws heavily on the deep dive profile — company profile, commercial strength, portfolio and pipeline analysis, corporate SWOT, product-specific clinical data, expected marketing messages, KOL perceptions, product TPP, relevant timeline, and product SWOT.
Each scenario needs a pre-planned response. This is one of the most valuable elements of the deep dive, and it's the one most often skipped.
If the competitor gets a broader label than expected, what's your response? If they price 20% below your product, how do you adjust your value proposition? If their safety data is cleaner than anticipated, what messages do you deploy?
Contingency plans developed proactively — before the competitive event occurs — are dramatically better than reactive scrambles. The brand team that has already debated the response to a competitor's favorable ODAC outcome can execute immediately. The team that hasn't will spend weeks aligning on a strategy while the competitor captures physician mindshare.
Ensuring scenario-based contingency plans are in place if competitors do something different is vital to success. In Formula 1 racing, understanding what competitors might do during a race is essential for core race planning. But the plans that win are the ones that account for what happens when conditions change.
The final element translates everything above into concrete actions. What do we do now, based on what we know?
This is where too many profiles stop short. They document the intelligence but don't close the loop to strategy. The action plan should specify: what actions to take, who owns them, what timelines apply, and what triggers would change the plan.
The action plan is not a wish list. It's a set of committed decisions with accountability. If the deep dive revealed that the competitor's clinical data supports a differentiation claim you haven't prepared for, the action plan specifies who is developing the counter-messaging, when it will be ready, and who approves it.
The deep dive framework above focuses on a specific competitive product in a specific indication. But competitive intelligence also requires company-level understanding.
A company-level profile addresses seven core questions:
1. Overall SWOT. What are the competitor's corporate strengths, weaknesses, opportunities, and threats? This is distinct from the product SWOT — it looks at the organization's broader strategic position.
2. Financial situation and investment capacity. What is the competitor's financial health? Are they flush with cash from a blockbuster product, or constrained by pipeline failures and patent cliffs? Their financial situation directly affects how aggressively they can invest in the product you're competing against.
3. Product position within broader portfolio. Is this the flagship compound or a secondary priority? A competitor where your shared indication represents 60% of their pipeline value will fight differently than one where it's a 5% bet.
4. Partnerships and external relationships. Who are they working with? Co-promotion agreements, licensing deals, academic partnerships, and CRO relationships all shape capability and strategic direction.
5. Organizational structure and leadership. Who makes the decisions? What's the leadership team's track record? A new CEO with a mandate to rationalize the portfolio might deprioritize the very asset you're worried about.
6. Commercialization capabilities. Do they have the field force, the market access team, the medical affairs infrastructure to launch and sustain a product in your indication? A strong molecule with no commercial engine behind it is a different threat than one backed by an established go-to-market machine.
7. Licensing agreements. What deals are in place that could affect the competitive landscape? Out-licensing deals signal where the competitor sees geographic or commercial limitations. In-licensing deals signal where they're investing.
This company-level understanding provides the strategic context for every product-level assessment. Without it, you're profiling assets in a vacuum.
Product profiles are the workhorse of CI analysis. Every competitor product in your landscape should have a profile that covers the core elements.
Mechanism of action — how the drug works and how it differentiates from alternatives.
Clinical data — efficacy, safety, and tolerability results from published trials and conferences.
Label and regulatory status — what the product is approved for, what indications are being pursued, and where regulatory submissions stand.
Pricing and market access — list price, net price where knowable, reimbursement status, formulary positioning. What is their pricing strategy compared to ours? What HEOR evidence supports their value proposition?
Market share and commercial performance — current uptake, growth trajectory, prescriber adoption patterns.
Differentiation claims — what the competitor says about their product and how it compares to the narrative you're building.
Clinical trial profiles sit alongside product profiles. They track each active competitor trial: design, endpoints, enrollment, key investigators, expected completion dates, and results as they become available.
The exercise of building product profiles is itself illuminating. In the analyst training we run, analysts build profiles for real-world products — starting with identifying the target company, then mapping product indications, key clinical trials, timelines, key issues and opportunities, future plans, and key partnerships. The process of systematically working through each element almost always surfaces intelligence gaps that weren't visible before.
Intelligence requirements for product profiles span six categories: clinical (development phases, trial designs, results), financial (investment capacity, portfolio priorities), commercial (positioning, field force, launch plans), access and reimbursement (pricing, formulary, patient assistance), regulatory (submission timelines, agency requirements), and manufacturing/IP (patent status, supply chain, vertical structure).
A profile built in January and last updated in January is not a useful document in June. Competitor profiles have to be living documents with a defined update cadence.
Quarterly reviews should be aligned with competitor earnings calls. Every quarter, competitors publicly report financial results, provide pipeline updates, and sometimes signal strategic shifts. The quarterly analyst call prep — reviewing key competitive events, updating threat level assessments, and analyzing implications — is the minimum cadence for deep profile maintenance.
Event-triggered updates should supplement the quarterly rhythm. A competitor presents Phase III data at a medical congress. An FDA advisory committee meets to discuss their product. They announce a licensing deal or a leadership change. Each of these events should trigger a review and potential update of the relevant profile elements.
Key Competitor Indicators (KCIs) provide the monitoring framework between formal reviews. These are the signals worth watching continuously: clinical trial registry updates, patent filings, regulatory actions, job postings (which reveal capability-building), conference abstract acceptances, and investor day statements. Today, AI-powered monitoring can track these signals across thousands of sources and flag relevant changes as they happen.
from the pharma company's Enterprise Strategy captures the aspiration well: "I want AI to do the data gathering so I can spend time on strategic thinking." Applied to competitor profiling, that means automating the monitoring layer so that analysts can focus on interpretation and strategic implication — the parts that actually drive decisions.
The organizations that maintain current, analytically rich competitor profiles are the ones that see competitive events coming before they happen. The ones that don't are the ones reading about competitor launches in the trade press and scrambling to respond.
The framework above is straightforward. Applying it well is harder. A few patterns I see repeatedly:
Profiling too many competitors at the same depth. Resources are finite. Two excellent deep dives are worth more than ten superficial ones. Use the landscape view for breadth and the deep dive for the competitors that matter most.
Confusing description with analysis. The profile that lists everything the competitor has done is not the same as the profile that explains what they're likely to do next. Description is the input. Analysis is the output. The "so what" is what decision makers need.
Ignoring competitive asymmetry. Your competitor's view of the landscape may look completely different from yours. Understanding how they see you — and how that shapes their strategy — is part of the profiling exercise.
Treating the profile as a one-time project. Competitor profiles are not deliverables you hand off and move on from. They're living documents that degrade quickly without maintenance. If your deep dive was last updated six months ago, it's an artifact, not intelligence.
Separating the profile from the action. The most common failure. A beautifully structured, analytically sound profile that doesn't lead to a strategic action plan is a filing exercise. If the profile doesn't change what the brand team decides to do, it hasn't served its purpose.
AI is reshaping how competitor profiles are built and maintained, but not in the way most people assume.
The monitoring layer — tracking clinical trial updates, regulatory filings, patent changes, press releases, earnings call transcripts — is where AI creates the most immediate value. What used to require an analyst spending three hours a day scanning sources can now be automated. The technology crawls, processes, filters, and delivers what's relevant.
But the analytical layer — assessing threat level, interpreting trial design choices, building launch scenarios, developing contingency plans — remains human work. AI can surface patterns in the data. It can flag that a competitor has changed their enrollment criteria or added a new secondary endpoint. What it can't do is interpret what that change means for your positioning strategy.
of a mid-size pharmaceutical company describes the shift well. Before AI, his team relied on external vendors for competitive analysis — expensive and slow. Now they can establish strategy and test different assumptions at a fraction of the cost. The profile-building process that used to take weeks of research can now begin with an AI-generated baseline that an analyst refines and interprets.
The way I think about it: AI handles the episteme (what is known and provable) and the techne (the systematic production of analysis). What stays human is the phronesis — the contextual judgment, the ability to weigh ambiguity, the understanding of organizational dynamics that no model can replicate. A strong competitor profile requires all three.
A strategic competitor profile covers nine elements: strategic context, expected launch date, threat level assessment, competitor TPP comparison, registration clinical trial analysis, SWOT analysis, expected launch scenarios, contingency plans, and competitive strategic action plan. The structure deliberately moves from context to assessment to action — description alone is not enough.
Quarterly at minimum, aligned with competitor earnings calls and pipeline updates. Major events — Phase III data presentations, regulatory decisions, leadership changes, licensing deals — should trigger immediate updates. Between formal reviews, continuous monitoring of Key Competitor Indicators (clinical trial registry changes, patent filings, job postings) keeps the profile current.
Two to five direct competitors deserve deep-dive profiles. Beyond that, maintain broader landscape monitoring for indirect and potential competitors. The constraint is analytical capacity — a thorough deep dive requires significant time to build and maintain. Two excellent profiles are worth more than ten superficial ones.
A company profile assesses the competitor organization — financial health, portfolio strategy, leadership, commercial capabilities, partnerships. A product profile tracks a specific asset — mechanism of action, clinical data, label, pricing, market share. Both are needed. The company profile provides strategic context. The product profile provides competitive detail. Without the company-level view, you're assessing an asset in a vacuum.
Threat level is a function of three dimensions: clinical data strength (or expected data quality), commercial capability and organizational readiness, and timeline relative to yours. Each dimension is scored high, medium, or low. A competitor with strong Phase III data, an established commercial infrastructure, and a launch date ahead of yours is high threat. Threat levels should be reassessed at every major competitive event.
The CI function owns the profile as an analytical product. But inputs come from across the organization — medical affairs contributes clinical assessment, commercial contributes market dynamics, regulatory contributes filing intelligence. The deep dive is a cross-functional deliverable maintained by CI with input from the brand team.
AI automates the monitoring layer — tracking news, filings, trial updates, and conference presentations across hundreds of sources in near real-time. This dramatically reduces the time spent on data gathering. But the analytical work — threat assessment, scenario building, contingency planning — remains human. The organizations getting the most value from AI in profiling are the ones using the freed-up time for strategic analysis, not just producing the same profiles faster.
Salvador Carlucci is the founder of the Atacana Group and has spent over two decades building competitive intelligence functions for pharmaceutical and healthcare companies worldwide. He is co-author of the seminal articles on CI in biotech published in Nature Biotechnology.
© CompetitiveIntelligence.com